BioSpace News Archive

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced positive topline data from a Phase III clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional constipation (FC).

ADC Therapeutics SA announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley’s 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m. ET.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide.

IO Biotech announced that Mai-Britt Zocca, the company’s President and CEO, will be participating in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference, taking place September 12 – 14, 2022.

Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced that management will participate in two upcoming investor conferences in New York, NY.

OpGen, Inc., announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.

Context Therapeutics Inc. announced that Chief Executive Officer Martin Lehr will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference taking place virtually and in-person September 12-14, 2022, in New York City.

AIM ImmunoTech Inc. announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.

Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in New York, NY.

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.